Comparison of efficacy and safety of the secondary treatment with increased fesoterodine and with mirabegron combination with 4mg fesoterodine for those who still have moderate or more overactive bladder symptoms after the initial treatment with 4mg fesoterodine: preliminary study - Comparison of efficacy and safety between increased fesoterodine and mirabegron combination for the overactive bladder resistant to the initial fesoterodine treatment.

Dept. of Urology, Otsu Minicipal Hospital0 个研究点目标入组 60 人开始时间: 2013年9月17日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with the practice of catheterization past or present. 2) Residual urine volume is more than 100ml. 3) Patients who can`t urine voluntarily. 4) Neurogenic bladder, urethral stricture, urinary tract infection, urinary tract calculi, interstitial cystitis, chronic prostatitis, prostate cancer, bladder cancer 5) Patients who are contraindicated for fesoterodine administration. 6) Patients who are contraindicated for mirabegron administration. 7) Patients who have the history of the administration of contraindicated agents within 2 weeks.

发起方

Dept. of Urology, Otsu Minicipal Hospital